June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

June 10, 2025

Does Combination Therapy Improve Albuminuria?

Finerenone plus empagliflozin reduced urinary albumin-to-creatinine ratio by 29% to 32% more than either drug alone in patients with chronic kidney disease and type 2 diabetes.

Conexiant

June 09, 2025

NIH Staff Challenge Leadership's Research Policies

Federal scientists release formal dissent declaration opposing administration's grant terminations and policy changes affecting biomedical research.

Conexiant

June 02, 2025

New COVID Vaccine Approved for High-Risk Groups

After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

April 29, 2024

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.

Conexiant

November 11, 2024

Morning BP Rise Linked to Heart Hypertrophy

A morning BP rise of over 10 mmHg independently predicts left ventricular hypertrophy—accounting for 36.2% of LVMI variability, even after adjusting for age and BMI.

Conexiant

December 12, 2024

Brief, Vigorous Activity May Lower CV Risk in Women: Study Findings

A recent study shows that even 3.4 minutes of vigorous intermittent lifestyle physical activity per day could significantly reduce cardiovascular risk, particularly in non-exercising women.

Conexiant

November 01, 2024

Study: U.S. Faces Higher Drug Shortages

A recent study compared drug shortage risks between the U.S. and Canada, revealing that the U.S. experienced approximately a 40% higher drug shortage risk compared to Canada, with trends persisting both pre-pandemic and during COVID-19. The study highlighted that Canada's approach was associated with a lower shortage risk.

Conexiant